Format

Send to

Choose Destination
Br J Cancer. 2003 Nov 17;89(10):1817-21.

Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development.

Author information

1
Ontario Cancer Institute, University Health Network, Toronto, Canada.

Abstract

Matrix metalloproteinases (MMPs) were initially recognised for their extracellular matrix (ECM)-degrading capability during tissue remodelling. Their importance was further highlighted by their role in metastasis. Clinical trials have since evaluated the potential of MMP inhibitors as anticancer therapeutics, but without success. These initial studies point to the complex, multifunctional capacity of MMPs in cancer as shown by their function, not only as strident mediators of advanced malignancies, but also as effectors of early stage tumorigenesis. Research now shows that MMPs, and their tissue inhibitors, affect tumour initiation and growth through loss of cell adhesion, evasion of apoptosis, and deregulation of cell division. The extracellular nature of the metalloproteinase axis situates it as a master regulator of cell fate.

PMID:
14612884
PMCID:
PMC2394437
DOI:
10.1038/sj.bjc.6601327
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center